专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20040106591A1 Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia 失效
标题翻译：用于治疗HIV相关脂肪分布异常和高脂血症的组合物和方法
公开(公告)号：US20040106591A1
公开(公告)日：2004-06-03
申请号：US10699195
申请日：2003-10-31
发明人： Linda M. Pacioretty , John G. Babish
IPC分类号： A61K031/555 , A61K031/385 , A61K031/225 , A61K031/22
CPC分类号： A61K31/28 , A61K31/045 , A61K31/198 , A61K31/20 , A61K31/426 , A61K31/43 , A61K2300/00
摘要： Compositions for treating or preventing fat maldistribution or hyperlipidemia resulting from anti-retroviral treatment of HIV-1 infection are disclosed. The compositions contain a conjugated fatty acid or alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium. Methods of treating a subject suffering from HIV-associated fat maldistribution or hyperlipidemia by administering a composition that includes a conjugated fatty acid or conjugated fatty alcohol and at least one member selected from the group consisting of a thiol-containing compound and a bioavailable form of trivalent chromium are similarly provided.
摘要翻译：公开了用于治疗或预防由HIV-1感染的抗逆转录病毒治疗引起的脂肪分布不均或高脂血症的组合物。组合物含有共轭脂肪酸或醇和选自含硫醇化合物和生物可利用形式的三价铬的至少一种。通过施用包含共轭脂肪酸或共轭脂肪醇的组合物和至少一种选自含硫醇化合物和生物可利用形式的三价药物来治疗患有HIV相关脂肪分布异常或高脂血症的受试者的方法铬类似地提供。

12. 发明申请

US20040072820A1 Naphthyl compounds, intermediates, compositions, and methods of use 失效
标题翻译：萘基化合物，中间体，组合物和使用方法
公开(公告)号：US20040072820A1
公开(公告)日：2004-04-15
申请号：US10445482
申请日：2003-05-27
发明人： Henry Uhlman Bryant , Thomas Alan Crowell , Charles David Jones , Alan David Palkowitz
IPC分类号： A61K031/55 , A61K031/537 , A61K031/445 , A61K031/40 , A61K031/225
CPC分类号： C07D295/088 , C07C41/26 , C07C41/28 , C07C43/23 , C07C43/295 , C07C45/46 , C07C45/71 , C07C47/575 , C07C49/755 , C07C51/367 , C07C67/03 , C07C67/11 , C07C67/293 , C07C67/317 , C07C69/017 , Y02P20/55 , C07C59/68 , C07C69/18
摘要： The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.
摘要翻译：本发明提供新的取代的萘基化合物，中间体，组合物，药物制剂和使用方法。

13. 发明申请

US20040052874A1 Synergistic composition for treating leukemia 失效
标题翻译：协同治疗白血病的组合物
公开(公告)号：US20040052874A1
公开(公告)日：2004-03-18
申请号：US10613122
申请日：2003-07-07
申请人： Council Of Scientific & Industrial Research
发明人： Santu Bandyopadhyay , Bikash Chandra Pal , Samir Bhattacharya , Keshab Chandra Roy , Gautam Bandyopadhyay
IPC分类号： A61K035/78 , A61K038/00 , A61K031/70 , A61K031/366 , A61K031/225
CPC分类号： A61K45/06 , A61K31/192 , A61K31/215 , A61K31/216 , A61K31/225 , A61K31/235 , A61K31/366 , A61K31/70 , A61K31/716 , A61K36/67 , Y10S514/908 , A61K2300/00
摘要： The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts of Piper betel or any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.
摘要翻译：本发明提供一种治疗急性和慢性骨髓性白血病（AML和CML）和淋巴样白血病的方法，所述方法包括给药药物组合物，其包含药用有效量的绿原酸（CA）和3-对 - 香豆素奎尼酸（PCQ）从Piper槟榔或任何其他来源的任何植物部分分离或独立地或以协同组合任选地与药学上可接受的添加剂分离。

14. 发明申请

US20040044076A1 Neutrophil imaging methods in cystic fibrosis 审中-公开
标题翻译：囊性纤维化中性粒细胞成像方法
公开(公告)号：US20040044076A1
公开(公告)日：2004-03-04
申请号：US10452925
申请日：2003-06-03
申请人： Immunomedics, Inc.
发明人： David Goldenberg
IPC分类号： A61K031/225
CPC分类号： A61K49/0058 , A61K47/6879 , A61K47/6881 , A61K49/0013 , A61K49/0021 , A61K49/0041 , A61K49/0043 , A61K49/006 , A61K49/0404 , A61K49/0433 , A61K49/16 , A61K49/227 , A61K51/0497 , A61K51/1027 , A61K51/1093
摘要： The present invention is directed to an improved method to detect and monitor a subject having cystic fibrosis (CF) by employing at least one anti-granulocyte/neutrophil antibody or a fragment thereof and a diagnostic agent via various imaging methods, wherein said anti-granulocyte antibody is not a murine MN-3 antibody Fabnull fragment that is radiolabeled with 99mTc. Pretargeting methods for improved imaging of granulocytes accumulated in CF are also described. It is further directed to a simple, noninvasive, and effective test that can assess neutrophil delivery to the lower airways of patients with CF and other neutrophil-mediated lung diseases.
摘要翻译：本发明涉及通过各种成像方法使用至少一种抗粒细胞/嗜中性粒细胞/中性粒细胞抗体或其片段和诊断剂来检测和监测具有囊性纤维化（CF）的受试者的改进方法，其中所述抗粒细胞抗体不是用99m Tc放射标记的鼠MN-3抗体Fab'片段。还描述了用于改进在CF中累积的粒细胞成像的预靶向方法。它进一步涉及一种简单，无创和有效的测试，可以评估中性粒细胞向CF和其他嗜中性粒细胞介导的肺部疾病患者的下呼吸道传递。

15. 发明申请

US20040044023A1 Compositions and methods for treating or preventing memory impairment 审中-公开
标题翻译：用于治疗或预防记忆障碍的组合物和方法
公开(公告)号：US20040044023A1
公开(公告)日：2004-03-04
申请号：US10231361
申请日：2002-08-30
发明人： Marc Cantillon
IPC分类号： A61K031/55 , A61K031/4745 , A61K031/473 , A61K031/401 , A61K031/366 , A61K031/225
CPC分类号： A61K31/473 , A61K31/225 , A61K31/366 , A61K31/401 , A61K31/4745 , A61K31/55 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions for treatment or prevention of memory impairment which comprise a cholinesterase inhibitor and at least one other pharmacologically active agent selected from HMG-CoA reductase inhibitors, cholesterol absorption inhibitors, gamma or beta secretase inhibitors, NMDA antagonists, muscarinic receptor agonists and nicotinic receptor agonists. Additionally, the present invention relates to the use of these pharmaceutical compositions to treat or prevent memory impairment in a mammal, such as a human.
摘要翻译：本发明涉及用于治疗或预防记忆障碍的药物组合物，其包含胆碱酯酶抑制剂和至少一种其它药理活性剂，其选自HMG-CoA还原酶抑制剂，胆固醇吸收抑制剂，γ或β分泌酶抑制剂，NMDA拮抗剂，毒蕈碱受体激动剂和烟碱受体激动剂。另外，本发明涉及这些药物组合物在哺乳动物（例如人）中治疗或预防记忆障碍的用途。

16. 发明申请

US20040006125A1 Bone growth compositions and methods 失效
标题翻译：骨生长组成和方法
公开(公告)号：US20040006125A1
公开(公告)日：2004-01-08
申请号：US10460645
申请日：2003-06-11
申请人： NeuroPro Technologies, Inc.
发明人： Benjamin J. Remington , David J. Bearss , Kavian Shahi
IPC分类号： A61K031/401 , A61K031/366 , A61K031/225
CPC分类号： A61F2/4455 , A61F2/28 , A61F2/4405 , A61F2002/2817 , A61F2002/30224 , A61F2002/30677 , A61F2230/0069 , A61F2310/00359 , A61F2310/00365 , A61F2310/00796 , A61K9/0024 , A61K31/22 , A61K31/366 , A61K31/401 , A61L27/54 , A61L27/56 , A61L27/58 , A61L2300/434
摘要： The present invention provides an improved technique for spinal fusion involving the administration of an HMG-CoA reductase inhibitor to a fusion. The HMG-CoA reductase inhibitor is preferably delivered to the site by a carrier. More preferably, the HMG-CoA reductase inhibitor is delivered to the site by a non-compressible delivery vehicle. The invention is suitable for promoting non-anatomic or heterotopic bone growth between any bony surfaces where bone growth is desired but does not naturally occur.
摘要翻译：本发明提供了一种改进的涉及将HMG-CoA还原酶抑制剂施用于融合物的脊柱融合技术。 HMG-CoA还原酶抑制剂优选通过载体递送到该位点。更优选地，HMG-CoA还原酶抑制剂通过不可压缩递送载体递送到该位点。本发明适用于在需要但不天然发生骨生长的任何骨表面之间促进非解剖或异位骨生长。

17. 发明申请

US20030211151A1 Dihydroxy open-acid and salts of HMG-Co-A reductase inhibitors 审中-公开
标题翻译：二羟基开酸和HMG-Co-A还原酶抑制剂的盐
公开(公告)号：US20030211151A1
公开(公告)日：2003-11-13
申请号：US10425154
申请日：2003-04-29
申请人： Merck & Co., Inc.
发明人： Richard D. Tillyer , Paul J. Reider , Edward J. J. Grabowski , Feng Xu , Jose M. Vega , Mandana Asgharnejad
IPC分类号： A61K031/225 , A61K009/22 , A61K009/16 , A61K009/50
CPC分类号： A61K9/2833
摘要： The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.
摘要翻译：本发明提供用于抑制HMG-CoA还原酶的方法和药物组合物，以及用于治疗和/或降低受HMG-CoA还原酶抑制影响的疾病和病症的风险，包括口服施用治疗有效量的选择的化合物从延迟释放药物剂型的二羟基开酸他汀类药物及其药学上可接受的盐或酯到需要这种治疗的患者，其中化合物从剂型中的实质性释放被延迟直到剂型通过后肚子

18. 发明申请

US20030203854A1 Composition for effecting serum cholesterol levels 审中-公开
标题翻译：用于影响血清胆固醇水平的组合物
公开(公告)号：US20030203854A1
公开(公告)日：2003-10-30
申请号：US10131620
申请日：2002-04-23
发明人： Ivo Pischel , Herbert Clinton Fairow , Ralf Jager
IPC分类号： A61K031/7024 , A61K031/202 , A61K031/16 , A61K031/225
CPC分类号： A61K31/16 , A23D7/0053 , A23D7/0056 , A23D7/011 , A23D7/013 , A23D9/007 , A23D9/013 , A23L27/60 , A23L33/11 , A23V2002/00 , A61K9/0056 , A61K9/1075 , A61K9/127 , A61K9/2009 , A61K9/2013 , A61K31/20 , A61K31/202 , A61K31/225 , A61K31/575 , A61K31/7024 , A61K45/06 , C07J9/00 , A23V2250/2136 , A23V2250/61 , A23V2250/642 , A23V2250/1628 , A23V2250/161
摘要： A new composition for effecting serum cholesterol levels is claimed, said composition comprising a) at least a waxy acid with 23 to 50 carbon atoms or derivatives thereof and with serum cholesterol level reducing properties, and b) 0 to 99.99% by weight of at least a component with serum cholesterol level effecting properties, and c) 0 to 20% by weight of at least a pharmaceutically acceptable formulation aid. The efficacy of this composition can be enhanced by further incorporation of other cholesterol reducing agents, like lecithin, tocotrienol, saponins, fibers, long-chain waxy alcohols and niacin. The claimed composition combines the benefits of the single physiolocology active constituence together with the technology to increase the biovailability.
摘要翻译：所要求的用于实现血清胆固醇水平的新组合物，所述组合物包含a）至少一种具有23-50个碳原子的蜡酸或其衍生物，并具有降低血清胆固醇水平的性质，以及b）至少0至99.99重量％具有影响血清胆固醇水平的组分，以及c）0至20重量％的至少一种药学上可接受的制剂助剂。通过进一步掺入其它胆固醇降低剂如卵磷脂，生育三烯酚，皂角苷，纤维，长链蜡质醇和烟酸，可以提高该组合物的功效。所声称的组合结合了单一生理活动选区的优点以及提高生物利用度的技术。

19. 发明申请

US20030186994A1 Combination of statins and sorbitol dehydrogenase inhibitors 审中-公开
标题翻译：他汀类和山梨醇脱氢酶抑制剂的组合
公开(公告)号：US20030186994A1
公开(公告)日：2003-10-02
申请号：US09974414
申请日：2001-10-09
发明人： Banavara L. Mylari
IPC分类号： A61K031/505 , A61K031/401 , A61K031/366 , A61K031/225
CPC分类号： A61K45/06 , A61K31/40 , A61K2300/00
摘要： This invention relates to pharmaceutical compositions comprising combinations of a statin, a prodrug thereof or a pharmaceutically acceptable salt of said statin or said prodrug and a sorbitol dehydrogenase inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said sorbitol dehydrogenase inhibitor or said prodrug, kits containing such combinations and methods of using such combinations to treat mammals, including humans, suffering from atherosclerosis and/or diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic cardiomyopathy, diabetic retinopathy, diabetic microangiopathy, diabetic macroangiopathy, cataracts or foot ulcers.
摘要翻译：本发明涉及药物组合物，其包含他汀类药物，其前体药物或所述他汀类药物或所述前药的药学上可接受的盐和山梨醇脱氢酶抑制剂，其前药或所述山梨醇脱氢酶抑制剂或所述前药的药学上可接受的盐，包含使用这种组合来治疗动脉粥样硬化和/或糖尿病并发症如糖尿病性肾病，糖尿病性肾病，糖尿病性视网膜病，糖尿病性微血管病，糖尿病性大血管病，白内障或足部溃疡的哺乳动物的组合和方法。

20. 发明申请

US20030175237A1 Method for the reduction of fasting plasma glucose and hemoglobin AIC levels 审中-公开
标题翻译：降低空腹血糖和血红蛋白AIC水平的方法
公开(公告)号：US20030175237A1
公开(公告)日：2003-09-18
申请号：US10375202
申请日：2003-02-26
发明人： William L. Bailey , Mark A. Wingertzahn , Jeffrey T. Jewell
IPC分类号： A61K031/785 , A61K031/225 , A61K031/401 , A61K031/366
CPC分类号： A61K31/366 , A61K31/225 , A61K31/401 , A61K31/785 , A61K2300/00
摘要： A method of reducing levels of fasting plasma glucose and/or hemoglobin A1C in patients by the administration of an aliphatic amine polymer, such as colesevelam HC1, either alone or in combination with a statin. In particular, the invention reduces LDL-cholesterol, FPG and HbA1c in patients with or without glucose intolerance. Also, the invention provides a method of treating hyperglycemia and prevent or delay associated microvasular complications in patients with impaired fasting glucose, T2DM and insulin resistance.
摘要翻译：通过单独或与他汀组合施用脂肪族胺聚合物（如colesevelam HC1）来降低患者空腹血浆葡萄糖和/或血红蛋白A1C水平的方法。特别地，本发明在有或无葡萄糖不耐受的患者中降低LDL-胆固醇，FPG和HbA1c。此外，本发明提供了治疗高血糖并预防或延迟患有空腹血糖，T2DM和胰岛素抵抗的患者的相关微血管并发症的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式